	US 11,773,178 B2
	Antagonistic CD40 monoclonal antibodies and uses thereof
Aaron Yamniuk, Vancouver (CA); Mary Struthers, Edison, NJ (US); Stanley R. Krystek, Jr., Ringoes, NJ (US); Akbar Nayeem, Newtown, PA (US); and Ginger Rakestraw, Somerville, MA (US)
Assigned to Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed by Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed on Jan. 31, 2022, as Appl. No. 17/588,518.
Application 17/588,518 is a division of application No. 16/686,596, filed on Nov. 18, 2019, granted, now 11,261,258.
Claims priority of provisional application 62/769,514, filed on Nov. 19, 2018.
Prior Publication US 2022/0153856 A1, May 19, 2022
Int. Cl. C12N 15/63 (2006.01); C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); C07K 16/46 (2006.01); A61P 37/00 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01); C07K 14/705 (2006.01)

CPC C07K 16/2878 (2013.01) [A61K 39/3955 (2013.01); A61K 47/68 (2017.08); A61K 47/6849 (2017.08); A61P 37/00 (2018.01); C07K 16/468 (2013.01); C12N 15/63 (2013.01); A61K 45/06 (2013.01); A61K 47/6803 (2017.08); A61K 2039/505 (2013.01); C07K 14/70578 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/71 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

17 Claims

1. A nucleic acid molecule encoding an isolated antibody or antigen binding portion thereof, that specifically binds to human CD40, wherein said antibody comprises a first polypeptide portion comprising a heavy chain variable region, and a second polypeptide portion comprising a light chain variable region, wherein:

said heavy chain variable region comprises a CDR1 comprising SEQ ID NO: 1, a CDR2 comprising SEQ ID NO: 12, and a CDR3 comprising SEQ ID NO: 3; and

said light chain variable region comprises a CDR1 comprising SEQ ID NO: 7, a CDR2 comprising SEQ ID NO: 8, and a CDR3 comprising SEQ ID NO: 9.